What is the recommended method to transition a patient from Concerta 54 mg (methylphenidate) to Jornay (methylphenidate)?

Transitioning from Concerta 54 mg to Jornay PM

Do not substitute Jornay PM for Concerta on a milligram-per-milligram basis; instead, discontinue Concerta 54 mg and start Jornay PM at 20 mg in the evening, then titrate upward weekly by 20 mg increments based on response. 1

Key Principle: Different Pharmacokinetic Profiles

• Jornay PM and Concerta have fundamentally different pharmacokinetic profiles and methylphenidate base compositions, which is why direct dose conversion is explicitly contraindicated by the FDA. 1
• Concerta uses an ascending-release delivery system taken in the morning, while Jornay PM is a delayed- and extended-release formulation taken in the evening (6:30–9:30 PM) to provide symptom control the following morning and throughout the day. 1

Step-by-Step Transition Protocol

1. Discontinue Concerta Completely

• Stop the current Concerta 54 mg regimen entirely before initiating Jornay PM. 1
• There is no tapering requirement for methylphenidate products when switching formulations in stable patients.

2. Start Jornay PM at 20 mg

• Begin with 20 mg once daily in the evening, regardless of the previous Concerta dose. 1
• Initial dosing time should be 8:00 PM (the most common time used in clinical trials), with flexibility to adjust between 6:30 PM and 9:30 PM based on next-day tolerability and efficacy. 1

3. Titrate Weekly in 20 mg Increments

• Increase the dose by 20 mg each week if symptom control is inadequate. 1
• The maximum studied and recommended dose is 100 mg daily. 1
• Most patients in the 54 mg Concerta range will likely require 40–60 mg of Jornay PM, but this must be determined through systematic titration rather than assumed equivalence.

4. Optimize Timing

• Once the effective dose is established, fine-tune the administration time (within the 6:30–9:30 PM window) to optimize morning onset and all-day coverage. 1
• Maintain consistent timing once optimized, and advise taking consistently with or without food. 1

Critical Monitoring Points

Pretreatment Screening

• Cardiac assessment: Obtain careful personal and family history of sudden death, ventricular arrhythmia, and structural heart disease; perform physical examination. 1
• Tic/Tourette evaluation: Assess family history and clinically evaluate for motor or verbal tics before starting Jornay PM. 1

During Titration

• Monitor for paradoxical aggravation of symptoms or adverse reactions; if these occur, reduce dose or discontinue. 1
• If no improvement is observed after appropriate dosage adjustment over one month, discontinue Jornay PM. 1
• Cardiovascular monitoring: Greater increases in blood pressure during early methylphenidate administration may predict better long-term symptom reduction, so track vital signs at each visit. 2

Common Pitfalls to Avoid

• Do not assume 54 mg Concerta = 54 mg Jornay PM: The FDA explicitly warns against milligram-per-milligram substitution due to different release mechanisms and methylphenidate base content. 1
• Do not take Jornay PM in the morning: This formulation is designed for evening administration only; morning dosing will result in inappropriate timing of symptom control. 1
• Do not split or chew capsules: Jornay PM must be swallowed whole or sprinkled entirely onto applesauce and consumed immediately without chewing. 1
• Do not confuse generic bioequivalence with clinical equivalence: Even among Concerta generics, significant differences in dissolution profiles and patient-reported outcomes have been documented, so brand-to-brand switches require clinical vigilance. 3, 4, 5

Rationale for Conservative Starting Dose

• Starting at 20 mg rather than attempting dose conversion minimizes risk of adverse effects from the different delivery system. 1
• Jornay PM's delayed-release mechanism means plasma levels and clinical effects differ substantially from Concerta's morning-dosed ascending profile. 1
• Systematic titration allows identification of the minimum effective dose for each patient, which may be higher or lower than anticipated based on prior Concerta dosing. 1

Long-Term Considerations

• Tolerance is not a clinical concern: Most patients maintain therapeutic response on stable doses for months to years without requiring systematic dose escalation. 6
• Growth monitoring: Long-term methylphenidate use, particularly in prepubertal children, has been associated with modest increases in BMI and small reductions in adult height, warranting regular growth parameter tracking. 7
• Abuse potential: Both formulations carry high abuse/misuse risk; reassess each patient's risk throughout treatment and monitor for signs of diversion or misuse. 1